Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

IMMUNOTHERAPY

Persistence of ex vivo expanded tumour and pathogen specific T-cells after allogeneic stem cell transplant for myeloid malignancies (the INTACT study)

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Study schema and clinical outcomes.
Fig. 2: Tracking antigen-specific T-cell responses by tetramer and TCR sequencing.

References

  1. Phelan R, Arora M, Chen M. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slides: Center for International Blood & Marrow Transplant Research; 2020 [updated 2020. Available from: https://www.cibmtr.org/ReferenceCenter/SlidesReports/SummarySlides/pages/index.aspx.

  2. Hill JA, Mayer BT, Xie H, Leisenring WM, Huang M-L, Stevens-Ayers T, et al. The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality. Blood. 2017;129:2316–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Qin Y, Zhu H, Jiang B, Li J, Lu X, Li L, et al. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease. Leuk Res. 2009;33:384–90.

    Article  CAS  PubMed  Google Scholar 

  4. Lee KH, Gowrishankar K, Street J, McGuire HM, Luciani F, Hughes B, et al. Ex vivo enrichment of PRAME antigen-specific T cells for adoptive immunotherapy using CD137 activation marker selection. Clin Transl Immunol. 2020;9:e1200.

    Article  CAS  Google Scholar 

  5. Castellano-González G, McGuire HM, Luciani F, Clancy LE, Li Z, Avdic S, et al. Rapidly expanded partially HLA DRB1-matched fungus-specific T cells mediate in vitro and in vivo antifungal activity. Blood Adv. 2020;4:3443–56.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Jiang W, Clancy LE, Avdic S, Sutrave G, Street J, Simms R, et al. Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant. Blood Adv. 2022;6:4949–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Strioga M, Pasukoniene V, Characiejus D. CD8+ CD28- and CD8+ CD57+ T cells and their role in health and disease. Immunology. 2011;134:17–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. McGuire HM, Rizzetto S, Withers BP, Clancy LE, Avdic S, Stern L, et al. Mass cytometry reveals immune signatures associated with cytomegalovirus (CMV) control in recipients of allogeneic haemopoietic stem cell transplant and CMV-specific T cells. Clin Transl Immunol. 2020;9:e1149.

    Article  CAS  Google Scholar 

  9. Papadopoulou A, Gerdemann U, Katari UL, Tzannou I, Liu H, Martinez C, et al. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014;6:ra83.

    Article  Google Scholar 

  10. Spyridoula V, Anne MT, Manik K, Shivani SM, Ayumi W, Premal L, et al. Rapid generation of multivirus-specific T lymphocytes for the prevention and treatment of respiratory viral infections. Haematologica. 2020;105:235–43.

    Article  Google Scholar 

  11. Gottlieb DJ, Clancy LE, Withers B, McGuire HM, Luciani F, Singh M, et al. Prophylactic antigen-specific T-cells targeting seven viral and fungal pathogens after allogeneic haemopoietic stem cell transplant. Clin Transl Immunol. 2021;10:e1249.

    Article  CAS  Google Scholar 

  12. Ma CK, Blyth E, Clancy L, Simms R, Burgess J, Brown R, et al. Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation. Cytotherapy. 2015;17:1406–20.

    Article  CAS  PubMed  Google Scholar 

  13. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115:925–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Roex MCJ, van Balen P, Germeroth L, Hageman L, van Egmond E, Veld SAJ, et al. Generation and infusion of multi-antigen-specific T cells to prevent complications early after T-cell depleted allogeneic stem cell transplantation-a phase I/II study. Leukemia. 2020;34:831–44.

    Article  CAS  PubMed  Google Scholar 

  15. Huisman W, Roex MCJ, Hageman L, Koster EAS, Veld SAJ, Hoogstraten C, et al. Tracking the progeny of adoptively transferred virus-specific T cells in patients posttransplant using TCR sequencing. Blood Adv. 2023;7:812–27.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was funded by the Australian National Health and Medical Research Council (NHMRC) (PG1088118). E.B. was an NHMRC Early Career Fellow (ECF1089398), a NSW Cancer Institute Early Career Fellow (ECF181576) and a current NSW Health Cell and Gene Therapy Fellow. WJ was supported by a scholarship from the Haematology Society of Australia and New Zealand and Leukaemia Foundation Australia, and is a current Leukaemia Foundation Australia Fellow. We are grateful to Gillian Huang and Elissa Atkins for clinical trial management. Microchimerism assays, DNA quantification, and flow cytometry were performed at the Westmead Scientific Platforms, which are supported by the Westmead Research Hub, the Westmead Institute for Medical Research the Cancer Institute of New South Wales, the National Health and Medical Research Council, and the Ian Potter Foundation.

Author information

Authors and Affiliations

Authors

Contributions

EB and DJG designed the study and wrote the trial protocol. WJ, MG, CMB, KM, DJG and EB recruited and treated patients on the study. SA, RS and LEC performed T-cell product manufacturing. WJ, JS, KHL, GC-G, RS, RB and HMM performed correlative studies. WJ, SA, RS, EP, AC, NM, BG and EB performed data analysis. All authors contributed to the writing of and approved the final manuscript.

Corresponding author

Correspondence to Emily Blyth.

Ethics declarations

Competing interests

LEC, KM, EB, and DJG hold patents in adoptive cell therapy for opportunistic infection and malignancy. EB declares advisory board membership for IQVIA, Abbvie, MSD, Astellas, Novartis, BMS, Bastion Education and research funding from MSD. The remaining authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jiang, W., Avdic, S., Lee, K.H. et al. Persistence of ex vivo expanded tumour and pathogen specific T-cells after allogeneic stem cell transplant for myeloid malignancies (the INTACT study). Leukemia 37, 2330–2333 (2023). https://doi.org/10.1038/s41375-023-02033-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-023-02033-5

Search

Quick links